Ipsen Reorganizes Its US Neurology Platform and Confirms Its Goal to Become Profitable in the US in 2014

  Ipsen Reorganizes Its US Neurology Platform and Confirms Its Goal to Become
  Profitable in the US in 2014

Business Wire

PARIS -- June 14, 2013

Regulatory News:

Ipsen (Euronext: IPN; ADR: IPSEY) (Paris:IPN) today announced that, as part of
the accelerated execution of its strategy in the USA, the Group adopted a new
organizational model for the distribution of Dysport^® in therapeutic
indications.

With the growing importance of market access and payer driven decisions in
healthcare, Ipsen is shifting its business model toward account management in
the USA. As such, the Dysport^® sales force has been optimized and refocused
on key accounts, which will allow us to better serve physicians and patients.

Marc de Garidel, Chairman and CEO of Ipsen stated: “I would like to thank all
US employees for their commitment and drive in advancing Ipsen USA over the
last year. We are confident that the new account driven organization for
Dysport^® will help turn our US commercial operations profitable in 2014.”

The costs linked to this reorganization are not expected to be material for
the Group. Ipsen will provide additional details during its Half Year results
on 30 August 2013.

About Ipsen

Ipsen is a global specialty-driven pharmaceutical company with total sales
exceeding €1.2 billion in 2012. Ipsen’s ambition is to become a leader in
specialty healthcare solutions for targeted debilitating diseases. Its
development strategy is supported by 3 franchises: neurology, endocrinology
and uro-oncology. Moreover, the Group has an active policy of partnerships.
Ipsen's R&D is focused on its innovative and differentiated technological
platforms, peptides and toxins. In 2012, R&D expenditure totalled close to
€250 million, representing more than 20% of Group sales. The Group has close
to 4,900 employees worldwide. Ipsen’s shares are traded on segment A of
Euronext Paris (stock code: IPN, ISIN code: FR0010259150) and eligible to the
“Service de Règlement Différé” (“SRD”). The Group is part of the SBF 120
index. Ipsen has implemented a Sponsored Level I American Depositary Receipt
(ADR) program, which trade on the over-the-counter market in the United States
under the symbol IPSEY. For more information on Ipsen, visit www.ipsen.com.

Forward Looking Statement

The forward-looking statements, objectives and targets contained herein are
based on the Group’s management strategy, current views and assumptions. Such
statements involve known and unknown risks and uncertainties that may cause
actual results, performance or events to differ materially from those
anticipated herein. All of the above risks could affect the Group’s future
ability to achieve its financial targets, which were set assuming reasonable
macroeconomic conditions based on the information available today.

Moreover, the targets described in this document were prepared without taking
into account external growth assumptions and potential future acquisitions,
which may alter these parameters. These objectives are based on data and
assumptions regarded as reasonable by the Group. These targets depend on
conditions or facts likely to happen in the future, and not exclusively on
historical data. Actual results may depart significantly from these targets
given the occurrence of certain risks and uncertainties, notably the fact that
a promising product in early development phase or clinical trial may end up
never being launched on the market or reaching its commercial targets, notably
for regulatory or competition reasons. The Group must face or might face
competition from Generics that might translate into a loss of market share.

Furthermore, the Research and Development process involves several stages each
of which involves the substantial risk that the Group may fail to achieve its
objectives and be forced to abandon its efforts with regards to a product in
which it has invested significant sums. Therefore, the Group cannot be certain
that favourable results obtained during pre-clinical trials will be confirmed
subsequently during clinical trials, or that the results of clinical trials
will be sufficient to demonstrate the safe and effective nature of the product
concerned. The Group also depends on third parties to develop and market some
of its products which could potentially generate substantial royalties; these
partners could behave in such ways which could cause damage to the Group’s
activities and financial results. The Group cannot be certain that its
partners will fulfil their obligations. It might be unable to obtain any
benefit from those agreements. A default by any of the Group’s partners could
generate lower revenues than expected. Such situations could have a negative
impact on the Group’s business, financial position or performance.

The Group expressly disclaims any obligation or undertaking to update or
revise any forward looking statements, targets or estimates contained in this
press release to reflect any change in events, conditions, assumptions or
circumstances on which any such statements are based, unless so required by
applicable law.

The Group’s business is subject to the risk factors outlined in its
registration documents filed with the French Autorité des Marchés Financiers.

Contact:

Ipsen
Media
Didier Véron
Vice President, Public Affairs and Corporate Communications
Tel.: +33 (0)1 58 33 51 16
Fax: +33 (0)1 58 33 50 58
didier.veron@ipsen.com
or
Financial Community
Susheel Surpal
Group CFO
Tel.: +33 (0)1 58 33 51 28
Fax: +33 (0)1 58 33 50 63
susheel.surpal@ipsen.com
or
Thomas Peny-Coblentz
Investor Relations Manager
Tel.: +33 (0)1 58 33 56 36
Fax: +33 (0)1 58 33 50 63
thomas.peny-coblentz@ipsen.com
or
Brigitte Le Guennec
Media and Public Relations Officer
Tel.: +33 (0)1 58 33 51 17
Fax: +33 (0)1 58 33 50 58
brigitte.le.guennec@ipsen.com
or
Pierre Kemula
Vice President, Corporate Finance, Treasury and Financial Markets
Tel.: +33 (0)1 58 33 60 08
Fax: +33 (0)1 58 33 50 63
pierre.kemula@ipsen.com
 
Press spacebar to pause and continue. Press esc to stop.